Pharmaceutical composition for improving diabetic peripheral neuropathy

Abstract

The invention provides a pharmaceutical composition for improving diabetic peripheral neuropathy. The pharmaceutical composition is prepared by the following steps: preparing two groups of pharmaceutical compositions and selecting mice suffering from diabetes mellitus of the same type; the preparation method of the pharmaceutical composition comprises the following steps: adding 100mL of sodium chloride solution into 1mg of mecobalamin injection, carrying out intravenous drip, and carrying out intramuscular injection by adopting 40U of pancreatic kininogenase injection; the preparation method of the pharmaceutical composition comprises the following steps: adding 0.45 g of alpha-lipoic acid into 100 mL of a sodium chloride solution, and carrying out intravenous drip; the method comprises the following steps: selecting 53 mice with diabetes mellitus of the same type, and dividing the 53 mice into a research group and a control group; the clinical treatment effect, the adverse reaction occurrence rate and the sensory motor nerve conduction speed after treatment of the pharmaceutical composition used in a research group are obviously superior to those of a control group; the pharmaceutical composition used by the research group can block the neuropathy of diabetes mellitus through various ways and weaken the oxidation reaction of the disease, so that the nerve impulse conduction is accelerated, neuropeptides, nerve factors and the like are promoted to return to normal, and a good treatment effect is achieved.

Description

Technical Field

[0001] The invention belongs to the technical field of diabetes therapeutics, and particularly relates to a pharmaceutical composition for improving diabetic peripheral neuropathy. Background Art

[0002] Diabetic peripheral neuropathy is the most common complication of diabetes. It is relatively insidious and can occur in the early stages. The lesions generally affect the central and peripheral nerves. The main clinical symptoms include peripheral nerve damage with numbness and pain in the limbs. If early active treatment is not given in time, it will be more difficult to treat in the later stages and the effect will be even less ideal. Therefore, early diagnosis and treatment must be done to reduce the disability and mortality rates of the disease.

[0003] The core solution for diabetic peripheral neuropathy is causal treatment and symptomatic treatment, and the purpose is to improve diabetic peripheral neuropathy. At present, some scholars recommend the use of multiple drugs in combination for treatment, so continuous practical research is needed. In order to further explore the clinical effect of improving diabetic peripheral neuropathy, a drug composition for improving diabetic peripheral neuropathy is proposed. Summary of the invention

[0004] The invention provides a pharmaceutical composition for improving diabetic peripheral neuropathy, which solves the problems in the prior art.

[0005] The technical solution of the present invention is achieved as follows: a pharmaceutical composition for improving diabetic peripheral neuropathy, comprising: preparing two groups of pharmaceutical compositions and selecting mice with the same type of diabetes; Preparation of the pharmaceutical composition: 1 mg of methylcobalamin injection was added to 100 mL of sodium chloride solution for intravenous drip, and 40 U of pancreatic kallikrein injection was injected intramuscularly; Preparation of the pharmaceutical composition: 0.45 g of α-lipoic acid was added to 100 mL of sodium chloride solution for intravenous drip; Select mice with the same type of diabetes: Select 53 mice and divide them into two groups, namely the research group and the control group.

[0006] As a preferred embodiment of the pharmaceutical composition for improving diabetic peripheral neuropathy, the concentration of the 100 mL sodium chloride solution is 0.9%.

[0007] As a preferred embodiment of a pharmaceutical composition for improving diabetic peripheral neuropathy, the 1 mg methylcobalamin injection, 100 mL sodium chloride solution and 40 U kallikreinogenase injection should be taken once a day for three consecutive weeks, with a daily administration time deviation of ≤3h.

[0008] As a preferred embodiment of the pharmaceutical composition for improving diabetic peripheral neuropathy, 27 mice were selected from the 53 mice and entered the research group, and the remaining 26 mice entered the control group.

[0009] As a preferred embodiment of the pharmaceutical composition for improving diabetic peripheral neuropathy, the 53 mice had a daily quantitative diet and used insulin to control blood sugar, with fasting blood sugar ≤7.0mmol / L and postprandial blood sugar ≤10.0mmol / L.

[0010] As a preferred embodiment of the pharmaceutical composition for improving diabetic peripheral neuropathy, the motor nerve conduction velocity of the mice in the research group and the control group was recorded using an electromyograph.

[0011] After adopting the above technical scheme, the beneficial effect of the present invention is: the control group is treated with methylcobalamin and pancreatic kallikrein injection, and the research group is treated with methylcobalamin and α-lipoic acid. The results show that the research group is significantly superior to the control group in clinical treatment effect, incidence of adverse reactions and sensory motor nerve conduction velocity after treatment.

[0012] α-lipoic acid has a good effect on oxidative stress. When used with sodium chloride solution for intravenous drip, it can block diabetic neuropathy through multiple pathways, remove free radicals, regenerate antioxidant substances, and weaken the oxidative reaction that causes the disease. It can speed up the conduction of nerve impulses and promote the restoration of neuropeptides and nerve factors to normal, achieving a good therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0014] Figure 1 A comparison chart of the therapeutic effect of the present invention and the adverse reaction effect; Figure 2 This is a comparison diagram of nerve conduction velocity before and after treatment of the present invention; DETAILED DESCRIPTION

[0015] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Example

[0016] A pharmaceutical composition for improving diabetic peripheral neuropathy, comprising: preparing two groups of pharmaceutical compositions and selecting mice with the same type of diabetes; Preparation of the pharmaceutical composition: 1 mg of methylcobalamin injection was added to 100 mL of sodium chloride solution for intravenous drip, and 40 U of pancreatic kallikrein injection was injected intramuscularly; Preparation of the pharmaceutical composition: 0.45 g of α-lipoic acid was added to 100 mL of sodium chloride solution for intravenous drip; Select mice with the same type of diabetes: Select 53 mice and divide them into two groups, namely the research group and the control group.

[0017] Further, the concentration of 100 mL of sodium chloride solution is 0.9%.

[0018] Furthermore, 1 mg of methylcobalamin injection, 100 mL of sodium chloride solution, and 40 U of kallikrein injection should be administered once daily for three consecutive weeks, with a daily administration time deviation of ≤3 h.

[0019] Furthermore, 27 mice out of 53 were selected to enter the research group, and the remaining 26 mice entered the control group.

[0020] Furthermore, the daily diet of 53 mice was controlled, and blood sugar was controlled with insulin, with fasting blood sugar ≤7.0mmol / L and postprandial blood sugar ≤10.0mmol / L.

[0021] Furthermore, the motor nerve conduction velocity was recorded using an electromyograph in the research group and the control group mice.

[0022] According to the above scheme, 27 mice in the research group were treated with α-lipoic acid, by adding 0.45g of α-lipoic acid to 100mL of sodium chloride solution and intravenously dripping; while 26 mice in the control group were treated with methylcobalamin and kallikreinogenase injection, by adding 1mg of methylcobalamin injection to 100mL of sodium chloride solution and intravenously dripping, and at the same time, 40U of kallikreinogenase injection was injected intramuscularly.

[0023] The therapeutic effect, adverse reactions and sensory motor nerve conduction velocity after treatment were observed, analyzed and compared between the two groups of mice.

[0024] According to the attached Figure 1 The efficacy evaluation criteria are as follows: Markedly effective: The main clinical symptoms are significantly relieved and the muscle strength returns to normal or increases by more than 5.0 m / s compared with before treatment; Effective: The main clinical symptoms were alleviated, and the muscle strength increased by 5.0 m / s compared with before treatment; Ineffective: There is no change in the main clinical symptoms, or there is a deterioration.

[0025] The treatment effect and adverse reaction standards are: After treatment of mice in the study group, the therapeutic efficacy and adverse reaction incidence of patients in the study group were 87% (23 / 27) and 12% (3 / 27), respectively; The rates in the control group were 74% (19 / 26) and 35% (9 / 26) respectively. Statistical analysis showed that the treatment effects and the incidence of adverse reactions between the study group and the control group were significantly different.

[0026] According to the attached Figure 2 As shown, after treatment, the sensory motor nerve conduction velocity in the study group was significantly higher than that in the control group, with a significant difference; in addition, the sensory motor nerve conduction velocity in both the study group and the control group after treatment was significantly improved compared with before treatment, with a significant difference.

[0027] The results of α-lipoic acid treatment showed that it was significantly superior to methylcobalamin and kallikrein injection treatment in terms of clinical treatment effect, incidence of adverse reactions and sensory motor nerve conduction velocity after treatment.

[0028] Therefore, α-lipoic acid can play a very good role in oxidative stress. When combined with sodium chloride solution for intravenous drip, it can block diabetic neuropathy through multiple pathways, remove free radicals, regenerate antioxidant substances, and weaken the oxidative reaction that causes the disease. It can speed up the conduction of nerve impulses and promote the restoration of neuropeptides and nerve factors to normal, achieving a good therapeutic effect.

[0029] The present invention provides a pharmaceutical composition for improving diabetic peripheral neuropathy, which blocks diabetic neuropathy through multiple pathways, removes free radicals, regenerates antioxidant substances, and weakens the oxidative reaction of the disease. It accelerates the conduction of nerve impulses and promotes the restoration of neuropeptide nerve factors to normal, thus achieving a good therapeutic effect, bringing new ideas to the treatment of diabetic peripheral neuropathy and opening up a new application field of the pharmaceutical composition. The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.

[0030] The present invention provides a pharmaceutical composition for improving diabetic peripheral neuropathy. The above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition for improving diabetic peripheral neuropathy, characterized in that: include: Preparation of two groups of drug compositions and selection of mice with the same type of diabetes; Preparation of the pharmaceutical composition: 1 mg of methylcobalamin injection was added to 100 mL of sodium chloride solution for intravenous drip, and 40 U of pancreatic kallikrein injection was injected intramuscularly; Preparation of the pharmaceutical composition: 0.45 g of α-lipoic acid was added to 100 mL of sodium chloride solution for intravenous drip; Select mice with the same type of diabetes: Select 53 mice and divide them into two groups, namely the research group and the control group.

2. A pharmaceutical composition for improving diabetic peripheral neuropathy according to claim 1, characterized in that: The concentration of the 100 mL sodium chloride solution is 0.9%.

3. A pharmaceutical composition for improving diabetic peripheral neuropathy according to claim 1, characterized in that: The 1 mg methylcobalamin injection, 100 mL sodium chloride solution and 40 U kallikreinogenase injection should be taken once a day for three consecutive weeks, with a daily administration time deviation of ≤3 hours.

4. A pharmaceutical composition for improving diabetic peripheral neuropathy according to claim 1, characterized in that: 27 mice were selected from the 53 mice and entered the research group, and the remaining 26 mice entered the control group.

5. The pharmaceutical composition for improving diabetic peripheral neuropathy according to claim 1, characterized in that: The 53 mice were fed with a daily quantitative diet and their blood sugar was controlled with insulin, with fasting blood sugar ≤7.0mmol / L and postprandial blood sugar ≤10.0mmol / L.

6. The pharmaceutical composition for improving diabetic peripheral neuropathy according to claim 1, characterized in that: The motor nerve conduction velocity of the mice in the study group and the control group was recorded using an electromyograph.

Images